Aclaris Therapeutics Inc
NASDAQ:ACRS

  • LAST PRICE
    1.1900
  • TODAY'S CHANGE (%)
    0.0100 (0.8475%)
  • Bid / Lots
    1.1400/ 1
  • Ask / Lots
    1.2200/ 30
  • Open / Previous Close
    1.2000 / 1.1800
  • Day Range
    1.1500
    1.2000
  • 52 Week Range
    0.5902
    11.1200
  • Volume
    446,399

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 7, 2024

      Show headlines and story abstract

    • 4:07PM ET on Tuesday May 07, 2024 by MT Newswires
      Companies Mentioned: ACRS
      04:07 PM EDT, 05/07/2024 (MT Newswires) -- ...

    • 4:01PM ET on Tuesday May 07, 2024 by GlobeNewswire
      Companies Mentioned: ACRS

    • 4:01PM ET on Tuesday May 07, 2024 by Dow Jones
      Companies Mentioned: ACRS
      Licensing 1,031 1,061 Revaluation of contingent consideration 2,800 (800) ---------- ---------- Total costs and expenses 21,329 32,446 ---------- ---------- Loss from operations (18,931) (29,918) Other income, net 1,990 1,758 ---------- ---------- Net loss $ (16,941) $ (28,160) ========== ========== Net loss per share, basic and diluted $ (0.24) $ (0.42) ========== ========== Weighted average common shares outstanding, basic and diluted 71,074,858 66,872,778 (1) Amounts include stock-based compensation expense as follows: Cost of revenue $ 252 $ 299 Research and development (29) 2,602 General and administrative 1,866 3,905 Total stock-based compensation expense $ 2,089 $ 6,806 ========== ========== Aclaris Therapeutics, Inc. Selected Consolidated Balance Sheet Data (unaudited, in thousands, except share data) March 31, 2024 December 31, 2023 ---------------- --------------------- Cash, cash equivalents and marketable securities $ 161,365 $ 181,877 Total assets $ 174,065 $ 197,405 Total current liabilities $ 20,080 $ 30,952 Total liabilities $ 32,051 $ 40,226 Total stockholders' equity $ 142,014 $ 157,179 Common stock outstanding 71,248,017 70,894,889 Aclaris Therapeutics, Inc. Selected Consolidated Cash Flow Data (unaudited, in thousands) March 31, 2024 March 31, 2023 ---------------- ------------------ Net loss $ (16,941) $ (28,160) Depreciation and amortization 243 198 Stock-based compensation expense 2,089 6,806 Revaluation of contingent consideration 2,800 (800) Changes in operating assets and liabilities (9,006) (4,397) Net cash used in operating activities $ (20,815) $ (26,353) =========== ===========

    • 4:01PM ET on Tuesday May 07, 2024 by Dow Jones
      Companies Mentioned: ACRS
      Licensing 1,031 1,061 Revaluation of contingent consideration 2,800 (800) ---------- ---------- Total costs and expenses 21,329 32,446 ---------- ---------- Loss from operations (18,931) (29,918) Other income, net 1,990 1,758 ---------- ---------- Net loss $ (16,941) $ (28,160) ========== ========== Net loss per share, basic and diluted $ (0.24) $ (0.42) ========== ========== Weighted average common shares outstanding, basic and diluted 71,074,858 66,872,778 (1) Amounts include stock-based compensation expense as follows: Cost of revenue $ 252 $ 299 Research and development (29) 2,602 General and administrative 1,866 3,905 Total stock-based compensation expense $ 2,089 $ 6,806 ========== ========== Aclaris Therapeutics, Inc. Selected Consolidated Balance Sheet Data (unaudited, in thousands, except share data) March 31, 2024 December 31, 2023 ---------------- --------------------- Cash, cash equivalents and marketable securities $ 161,365 $ 181,877 Total assets $ 174,065 $ 197,405 Total current liabilities $ 20,080 $ 30,952 Total liabilities $ 32,051 $ 40,226 Total stockholders' equity $ 142,014 $ 157,179 Common stock outstanding 71,248,017 70,894,889 Aclaris Therapeutics, Inc. Selected Consolidated Cash Flow Data (unaudited, in thousands) March 31, 2024 March 31, 2023 ---------------- ------------------ Net loss $ (16,941) $ (28,160) Depreciation and amortization 243 198 Stock-based compensation expense 2,089 6,806 Revaluation of contingent consideration 2,800 (800) Changes in operating assets and liabilities (9,006) (4,397) Net cash used in operating activities $ (20,815) $ (26,353) =========== ===========

  • Apr 30, 2024

Peers Headlines